Introduction
============

Retinitis pigmentosa (RP, OMIM [268000](http://omim.org/entry/268000)) is the most common type of inherited retinal degeneration and is characterized by progressive degeneration of the photoreceptors. Epidemiological studies have consistently reported a frequency of approximately 1 in 3,000--5,000 individuals, without apparent ethnic or racial distinctions \[[@r1]\]. RP is both clinically and genetically heterogeneous. Clinically, symptoms usually emerge as night blindness during adolescence, progress to legal blindness by middle age and result in total loss of vision in later life. However, clinical features such as onset age and rate of progression have been documented to vary according to genetic background \[[@r2]\]. Genetically, RP can be transmitted in all inheritance patterns, and simplex cases represent 40%--50% of all RP patients \[[@r3]\]. To date, more than 40 genes causing nonsyndromic RP and 20 genes causing syndromic forms of RP have been identified. In addition to many RP genes, there are often several mutations at each locus, and different mutations within the same gene may cause different phenotypes \[[@r4]\]. Only a little more than 50% of RP cases can be explained by mutations in known genes \[[@r5]\]. This phenotypic and genetic heterogeneity of RP make its diagnosis highly complex and time consuming.

Mutation detection techniques that are exclusively PCR based are relatively inefficient, expensive, and labor intensive for genetic diagnosis. Therefore, different genotyping techniques such as microarray-based analysis and next-generation sequencing are useful for the detection of mutations associated with disorders showing high genetic and allelic heterogeneity. Recent mutation analysis studies using a genotyping microarray in patients with hereditary retinal diseases, including RP and Stargardt disease, have been reported for different ethnic groups \[[@r6]-[@r9]\]. However, there are no genotyping microarray data that establish the spectrum of RP mutations in the Asian population. Such data would be of great utility in providing effective genetic counseling and predicting disease severity for RP patients.

High-throughput, customized genotyping of targeted variants is desirable for biologically focused research \[[@r10]\]. For customized genotyping, assay reliability and productivity are considered the most important factors. The [GoldenGate](http://www.illumina.com/technology/goldengate_genotyping_assay.ilmn) assay has proven to be reliable and efficient for high-throughput genotyping of single-nucleotide polymorphisms. In this study, we designed and used a GoldenGate assay with VeraCode microbeads to screen for mutations in Korean patients with RP. In addition, we describe the clinical characteristics of patients with RP mutations.

Methods
=======

Subjects
--------

Informed consent was obtained from all participants before enrollment in the study, in accordance with the protocol approved by the Institutional Review Board at Seoul National University Hospital (SNUH) and at the Korea National Institute of Health. All protocols used in this study were also in full accordance with the tenets of the Declaration of Helsinki. A total of 696 subjects, 336 probands with nonsyndromic RP and 360 controls, were analyzed for 95 mutations of 28 RP genes. A summary of subjects' data are represented in [Table 1](#t1){ref-type="table"}. Patients with RP and their family members were recruited during the period 2006--2009 from the clinic for hereditary retinal degeneration at the Department of Ophthalmology, SNUH, Seoul, Korea and the Korean Retinitis Pigmentosa Society, a nonprofit support network for Korean RP patients \[[@r11]\]. Pedigrees of all patients were obtained through interviews. Controls were recruited from two population-based cohort studies at the Korea National Institute of Health \[[@r12]\]. Briefly, both cohorts were initiated in 2001 as part of the Korean Genome Epidemiology Study and designed to allow longitudinal prospective study. Genomic DNA was extracted from peripheral blood leukocytes using the FlexiGene DNA Kit ([Qiagen](http://www.qiagen.com/literature/render.aspx?id=382), Valencia, CA), in accordance with the manufacturer's instructions.

###### Summary of subjects

  **Group**   **Mode of inheritance**   **N (%)**   **Age\* (range)**   **Male (%)**
  ----------- ------------------------- ----------- ------------------- --------------
  RP          Autosomal dominant        62 (18)     41.5 (6--67)        30 (48)
              Autosomal recessive       60 (18)     41.0 (20--67)       38 (63)
              X-linked                  27 (8)      37.3 (7--65)        27 (100)
              Simplex                   144 (43)    35.9 (6--66)        92 (64)
              Unknown                   43 (13)     35.6 (6--59)        27 (63)
              Subtotal                  336 (100)   37.9 (6--67)        212 (63)
  Control                               360 (100)   63.7 (60--70)       180 (50)

\*mean age of subjects when they were recruited; N, total number tested

Assay design and genotyping
---------------------------

Twenty-eight genes carrying at least 350 previously described mutations associated with nonsyndromic RP were selected from the Human Gene Mutation Database ([HGMD](http://www.hgmd.cf.ac.uk/ac/index.php)) \[[@r13]\] and the [RetNet](http://www.sph.uth.tmc.edu/RetNet/) database in 2009. Mutations previously identified in patients with East Asian ancestry and/or reported in at least two independent research groups were preferred for the assay contents. A total of 95 assay probes for custom content were designed and optimized using the Illumina Assay Design Tool (Illumina, San Diego, CA; [Appendix 1](http://www.molvis.org/molvis/v18/a253/app-1.pdf)). A mutation with a high designability score was selected when multiple mutations were within 60 bp. The GoldenGate Genotyping Assay for VeraCode microbeads (Illumina) was used to screen mutations. Genotype calls were generated automatically using BeadStudio software version 3.3 (Illumina, San Diego, CA).

DNA sequencing
--------------

All variants detected in the GoldenGate assay were confirmed by sequence analysis. PCR primers were designed to amplify the regions of 12 mutations, using the reference sequences of PRP3 pre-mRNA processing factor 3 homolog (*PRPF3*; [NM_004698.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_004698.1)), rhodopsin (*RHO*; [NM_000539.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_000539.2)), phosphodiesterase 6B (*PDE6B*; [NM_000283.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_000283.2)), peripherin 2 (*PRPH2*; [NM_000322.3](http://www.ncbi.nlm.nih.gov/nuccore/NM_000322.3)), retinitis pigmentosa 1 (*RP1*; [NM_006269.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_006269.1)), and cone-rod homeobox containing gene (*CRX*; [NM_000554.4](http://www.ncbi.nlm.nih.gov/nuccore/NM_000554.4)). All primer sequences are available in [Appendix 2](http://www.molvis.org/molvis/v18/a253/app-2.pdf). Direct sequencing was performed with a BigDye Terminator Sequencing Kit and an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA) according to the manufacturer's protocols.

Ophthalmic examinations
-----------------------

RP was diagnosed by retina specialists at SNUH when a patient showed bilateral retinal degeneration with typical pigmentation on fundoscopic examination, or rod dysfunction on a standard electroretinogram (ERG) with degenerative retina. Ophthalmic examination included the best-corrected visual acuity, refraction, intraocular pressure measurement, slit-lamp biomicroscopy, fundoscopy, Goldmann perimetry, ERG, and optical coherence tomography (OCT; Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, CA). Refractive errors were measured with an autorefractometer and Goldmann perimetry with a V4e target was performed on all patients who were able to cooperate. ERG followed the guidelines of the International Society for Clinical Electrophysiology of Vision \[[@r14]\].

Mutation analysis
-----------------

The frequency of a mutant allele was assessed in both patients and controls. Segregation analysis of mutations was performed by sequence analysis when other family members were available. Sequence changes at the DNA or protein level are described according to the recommendations of the [Human Genome Variation Society](http://www.hgvs.org/mutnomen/). To predict the functional impact of missense mutations, [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/) and [SIFT](http://sift.jcvi.org/) software were used. The prediction result was classified into three types (probably damaging, possibly damaging, and benign) for [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/) \[[@r15]\] and two types (damaging and tolerated) for [SIFT](http://sift.jcvi.org/) software \[[@r16]\].

Results
=======

Mutation detection and validation
---------------------------------

We performed a mutation genotyping of RP genes using the GoldenGate assay for VeraCode microbeads. Twenty-eight genes carrying single-nucleotide mutations associated with nonsyndromic RP were selected to design the assay content in 2009. A total of 95 sequence variants (74 missense mutations, 20 nonsense mutations, and a nonstop change) were selected and analyzed in 336 unrelated patients with RP and 360 controls ([Figure 1](#f1){ref-type="fig"}). Of these, 28 mutations (30% of 95 assay contents) were previously identified in patients with East Asian ancestry. [Appendix 1](http://www.molvis.org/molvis/v18/a253/app-1.pdf) shows the list of mutations screened in the present study. Of 95 sequence variants tested, we failed to genotype five (5%) missense mutations (p.Y368H in retinal pigment epithelium-specific protein 65 kDa (*RPE65*); p.L12P in c-mer proto-oncogene tyrosine kinase (*MERTK*); p.G576D and p.L671P in *PDE6B*; and p.F1935L in *RP1*). The average call rate for 90 variants was 99.98%. Overall, 12 sequence variants of six genes (*PRPF3*, *RHO*, *PDE6B*, *PRPH2*, *RP1*, and *CRX*) were detected in 30 patients and 10 controls ([Table 2](#t2){ref-type="table"}). Of these, 11 mutations were previously found in Chinese, Japanese, or Korean RP patients. There was no sequence variation in the other 78 variants (87% of 90) tested in the Korean population, including the 360 controls.

![Schematic overview of the present study.](mv-v18-2398-f1){#f1}

###### Mutations identified in the present study

  **Gene**   **Amino acid**   **Nucleotide**   **Proband (336)**   **Control (360)**   **PolyPhen-2**   **SIFT**   **Reference**                                        
  ---------- ---------------- ---------------- ------------------- ------------------- ---------------- ---------- --------------- ------- --------------- ------------ -------------------
  PRPF3      p.T494M          c.1481C\>T       1                   0                   0.001            0          0               0       prob/prob       Damaging     \[[@r17],[@r38]\]
  RHO        p.T17M           c.50C\>T         1                   0                   0.001            0          0               0       prob/poss       \*Damaging   \[[@r18],[@r39]\]
             p.R135W          c.403C\>T        1                   0                   0.001            0          0               0       prob/prob       \*Damaging   \[[@r19],[@r20]\]
             p.D190N          c.568G\>A        1                   0                   0.001            0          0               0       poss/poss       \*Damaging   \[[@r21]\]
             p.K296N          c.888G\>T        1                   0                   0.001            0          0               0       prob/prob       \*Damaging   \[[@r18],[@r24]\]
             p.P347L          c.1040C\>T       2                   0                   0.003            0          0               0       poss/benign     \*Damaging   \[[@r18],[@r40]\]
  PDE6B      p.H557Y          c.1669C\>T       9                   4                   0.025            2          0               0.003   prob/prob       Damaging     \[[@r20],[@r22]\]
             p.T604I          c.1811C\>T       4                   0                   0.006            3          0               0.004   prob/prob       Damaging     \[[@r20]\]
  PRPH2      p.W316G          c.946T\>G        1                   0                   0.001            1          0               0.001   benign/benign   Damaging     \[[@r20]\]
  RP1        p.G706R          c.2116G\>C       1                   0                   0.001            1          0               0.001   benign/benign   Tolerated    \[[@r25]\]
             p.D984G          c.2951A\>G       1                   0                   0.001            0          0               0       poss/benign     Tolerated    \[[@r23]\]
  CRX        p.G122D          c.365G\>A        3                   0                   0.004            3          0               0.004   benign/benign   Tolerated    \[[@r20],[@r24]\]

Prediction by PolyPhen2 was performed using both HumDiv and HumVar data sets. \*Damaging, low confidence predictions with Median conservation above 3.25. Hetero, heterozygous mutation; Homo, homozygous mutation; prob, probably damaging; poss, possibly damaging.

All sequence variants identified in the genotyping assay were confirmed by bidirectional sequence analysis in all subjects with variants. Of 12 variants identified in the GoldenGate assay, three showed genotype inconsistency with the results of sequence analysis (p.T17M and p.K296N in *RHO*; and p.G122D in *CRX*). All heterozygous samples with these mutations were assigned the homozygous mutant genotype in the GoldenGate assay ([Figure 2](#f2){ref-type="fig"}).

![Genotype inconsistency between the GoldenGate assay (upper) and the sequence analysis (lower). In the GoldenGate assay, colored dots represent genotyped individuals (blue, a homozygote of reference allele; red, a homozygote of mutated allele; purple, a heterozygote; black, genotype fail).](mv-v18-2398-f2){#f2}

Mutation description and segregation
------------------------------------

Based on the segregation analysis, mutation frequency, and previous reports, 10 mutations in five genes were considered to be associated with RP in the Korean population (p.T494M in *PRPF3*; p.T17M, p.R135W, p.D190N, p.K296N and p.P347L in *RHO*; p.H557Y and p.T604I in *PDE6B*; p.W316G in *PRPH2*; p.D984G in *RP1*). We were able to perform genetic analyses of additional members of four families. In these families, we performed segregation analysis to test whether the mutation was disease causing. The respective pedigrees and allele statuses are shown in [Figure 3](#f3){ref-type="fig"}.

![Familial segregations of mutated alleles. The arrows indicate probands. Question marks represent individuals whose disease status has not been determined.](mv-v18-2398-f3){#f3}

### PRPF3

Mutations in the *PRPF3* gene have been associated with autosomal dominant RP (ADRP). In the present study, one missense mutation was observed in a family with ADRP. In family RP-0537, the heterozygous p.T494M mutation segregated with disease from the proband (II-1) to a daughter (III-2) and was not detected in a healthy son (III-1; [Figure 3A](#f3){ref-type="fig"}). This heterozygous mutation was previously reported as causative mutation in a Japanese family with ADRP \[[@r17]\] and was predicted to be pathogenic by computational analysis ([Table 2](#t2){ref-type="table"}).

### RHO

Rhodopsin mutations have been associated with ADRP or autosomal recessive RP (ARRP). In the present study, five missense mutations were detected in five different probands. Of these, three mutations (p.T17M, p.K296N, and p.P347L) previously identified in Korean RP patients \[[@r18]\] were included to verify the GoldenGate assay for mutation detection in the same subjects. The genetic and phenotypic characteristics of these three mutations were described in our previous report \[[@r18]\]. Except those patients, there were no subjects with these mutations in the present study.

The heterozygous p.R135W mutation was detected in a proband (III-2) of family RP-0089 ([Figure 3B](#f3){ref-type="fig"}). This heterozygous mutation has been previously reported as a causative mutation of ADRP in other populations \[[@r19],[@r20]\] and was predicted to be pathogenic by computational analysis ([Table 2](#t2){ref-type="table"}). Interestingly, both parents of the proband were patients with ADRP (mother, II-3) or ARRP (father, II-4). To confirm the mutation segregation, we analyzed the available affected relatives in the maternal and paternal pedigrees. Blood samples of the affected father (II-4) and an affected sister (II-2) of the mother were available. The heterozygous p.R135W mutation was identified in II-2 and not in his father (II-4) by direct sequencing. The disease-causing gene in the paternal pedigree is unknown to date.

The heterozygous p.D190N mutation was observed in a patient from an ADRP family but was not detected in the other subjects tested. This heterozygous mutation was previously reported as causative mutation in Sardinian families with ADRP \[[@r21]\] and was expected to be pathogenic in computational analysis ([Table 2](#t2){ref-type="table"}). As far as we know, this is the first report of the p.D190N mutation in an East Asian population.

### PDE6B

Variants in the phosphodiesterase 6B gene have been mainly associated with ARRP. This mutation has been previously reported as a causative mutation of ARRP \[[@r20],[@r22]\], and was predicted to be pathogenic in computational analysis ([Table 2](#t2){ref-type="table"}). In the present study, p.H557Y was the most frequent mutation, including four homozygous mutations in different patients ([Table 2](#t2){ref-type="table"}). The heterozygous carrier state was found in nine patients and two controls. In family RP-0187 with ARRP, a homozygous patient (II-1) had inherited mutations from both heterozygous carrier parents ([Figure 3C](#f3){ref-type="fig"}). The patient's two sons (III-1 and III-2) also carried the heterozygous p.H557Y mutation without disease.

Another missense mutation of *PDE6B*, p.T604I, was detected in four patients and three controls in the heterozygous state. No homozygous patient with the p.T604I mutation was observed in our study. A digenic pattern of RP with the heterozygous p.T604I mutation in the recessive *PDE6B* gene and the heterozygous p.G167S mutation in the dominant *PRPH2* gene was previously reported in Japanese patients \[[@r20]\]. However, there was no subject that exhibited these two heterozygous mutations simultaneously in our study.

### PRPH2

Some variants in the peripherin 2 gene have been associated with ADRP or digenic RP. In the present study, the heterozygous p.W316G mutation was observed in a patient and a control ([Table 2](#t2){ref-type="table"}). This heterozygous mutation was previously identified in a Japanese patient and was expected to be pathogenic from computational analysis \[[@r20]\]. The association of this mutation with RP could not be assessed in our study because the family history and segregation analysis were not available in subjects with this mutation.

### RP1

Variants in the *RP1* gene have been mostly associated with ADRP or ARRP. In the present study, the heterozygous p.D984G mutation was observed in one patient, but not in control chromosomes. The genes from three healthy relatives of the patient were sequenced and did not have the mutation ([Figure 3D](#f3){ref-type="fig"}). This mutation was previously reported in a Chinese ADRP family and was expected to be pathogenic \[[@r23]\].

Two missense mutations expected to be benign were detected in this study ([Table 2](#t2){ref-type="table"}). The p.G706R mutation in the *RP1* gene and p.G122D in the *CRX* gene were found in both patients and controls in the heterozygous state ([Table 2](#t2){ref-type="table"}). Although *RP1* and *CRX* are associated with ADRP, these mutations have been previously reported in other ethnic groups and were not expected to be pathogenic \[[@r20],[@r23]-[@r25]\].

Clinical evaluation in retinitis pigmentosa patients with missense mutations
----------------------------------------------------------------------------

The mutations and phenotypes are summarized in [Table 3](#t3){ref-type="table"}. The patients ranged in age from 22 to 51 years.

###### Phenotypic characterization of patients with missense mutation.

  **Gene**   **Mutation**   **Family**   **Patient**    **Age**   **BCVA:**   **Lens opacities:**   **Visual field**   **ERG:**   **OCT (CFT, µm):**
  ---------- -------------- ------------ -------------- --------- ----------- --------------------- ------------------ ---------- --------------------
                            ID           ID             /Sex      RE/LE       RE/LE                                    Cone/Rod   RE/LE
  PRPF3      p.T494M        RP-0537      R0537, II-1    49/F      0.02/0.02   Clear                 Central\<5°        ND/ND      184,CME/355,VMT
             p.T494M        RP-0537      R0553, III-2   27/F      0.6/0.6     Clear                 Central 10°        ND/ND      ―
  ?          ?              RP-0089      R0089, II-4    49/M      0.2/0.2     NS                    Central 5°\~10°    ND/ND      ―
  RHO        p.R135W        RP-0089      R0352, II-2    45/F      HM/HM       IOL                   Failure            ND/ND      178/140
             p.R135W        RP-0089      R0119, III-2   22/M      0.4/0.6     Clear                 Pph.constriction   ND/ND      ―
             p.D190N        RP-0513      R0513          59/M      0.2/0.4     PSC                   Central 5°\~10°    ↓↓/ND      256/347,ERM
  PDE6B      p.H557Y        RP-0187      R0187, II-1    51/M      0.02/0.04   IOL/NS                Central 5°\~10°    ND/ND      201/187
             p.H557Y        RP-0143      R0143          26/F      0.9/0.4     Clear                 Central 10°        ―          263,ERM/244,CME
             p.H557Y        RP-0295      R0295          28/F      0.7/0.4     Clear                 ―                  ―          ―
             p.H557Y        RP-0310      R0310          32/F      0.5/0.5     ASC                   Pph.constriction   ―          ―
  PRPH2      p.W316G        RP-0030      R0030          33/M      0.2/0.2     Clear                 Central\<5°        ND/ND      ―
  RP1        p.D984G        RP-0121      R0121, II-1    29/M      0.02/0.04   IOL/PSC               ―                  ND/ND      181/109

BCVA, best corrected visual acuity (decimal); CFT, central foveal thickness (μm); CME, cystoid macular edema; ERM, epiretinal membrane; ERG, electroretinogram; HM, hand motion; IOL, intraocular lens; LE, left eye; ND, non-detectable; NS, nuclear sclerosis; OCT, optical coherence tomography; PSC, posterior subcapsular opacity; RE, right eye; VMT, vitreomacular traction.

### PRPF3, p.T494M

No lens opacities were found in a family with this mutation. Fundus findings of a 27-year-old daughter showed areas of atrophy along the arcades ([Figure 4A](#f4){ref-type="fig"}). OCT images from the mother showed cystoid macular edema (CME) in the right eye (RE) and vitreotraction membrane in the left eye (LE; [Figure 4B](#f4){ref-type="fig"}).

![Fundus photographs (**A, C: E, G:** and spectral domain optical coherence tomography images **B**: **D: F: H-J:** in retinitis pigmentosa patients with missense mutations. In fundus images, areas of atrophy along the arcades (**A**; red arrowheads) and marked pigmentary changes **E**: were noted. In optical coherence tomography (OCT) images, intraretinal cyst or cystoid macular edema (CME; **B**: **I:**; red arrow), severe foveal atrophy **D**: **H: J:** and normal range of foveal thickness **F**: were observed.](mv-v18-2398-f4){#f4}

### RHO, p.R135W

A 45-year-old woman showed poor visual acuity of hand motion in both eyes, although she had already undergone cataract surgery. The fundus examination showed severe retinal pigmentary degeneration involving the macula ([Figure 4C](#f4){ref-type="fig"}). OCT revealed severe foveal atrophy in both eyes, a 178 μm in the RE and 140 μm in the LE ([Figure 4D](#f4){ref-type="fig"}). The patient's cousin, aged 22 years, had decreased visual acuity of 0.4 in the RE and 0.6 in the LE, and showed peripheral constriction of the visual field.

### RHO, p.D190N

In spite of being the oldest subject and having cataracts, especially of the posterior subcapsular type, a 59-year-old patient maintained relatively good visual acuity of 0.2 in the RE and 0.4 in the LE. Moreover, the cone response in ERG was not yet extinguished. Marked pigmentary changes were seen in the whole retina, except the macula ([Figure 4E](#f4){ref-type="fig"}). OCT images showed a normal range of foveal thickness in the RE ([Figure 4F](#f4){ref-type="fig"}) and mild epiretinal membrane in the LE.

### PDE6B, p.H557Y

A 51-year-old patient had undergone cataract surgery in the RE and had foveal atrophy in both eyes ([Figure 4G,H](#f4){ref-type="fig"}). OCT images from a 26-year-old patient showed CME in the LE ([Figure 4I](#f4){ref-type="fig"}). Mild cataract, particularly anterior subcapsular opacity, was observed in a 32-year-old patient.

### PRPH2, p.W316G

A 33-year-old patient had decreased visual acuity of 0.2 and a severely constricted visual field, with less than the central 5° of radius remaining in each eye.

### RP1, p.D347G

A 29-year-old patient had very poor visual acuity of 0.02 in the RE and 0.04 in the LE, and slit-lamp examination showed an intraocular lens in the RE and cataract in the LE. Marked foveal atrophy was noticed in OCT images, although the patient was of young age, at 181 μm in the RE and 109 μm in the LE ([Figure 4J](#f4){ref-type="fig"}). When we compared OCT findings among similarly aged RP patients with missense mutations, foveal atrophy was more severe in patients with p.D347G in *RP1* or p.R135W in *RHO* than in those with p.T494M in *PRPF3* or p.H557Y in *PDE6B*. CME was observed in patients with p.T494M in *PRPF3* and p.H557Y in *PDE6B*.

Discussion
==========

Owing to the high genetic heterogeneity of RP, identification of its genetic cause is expensive and time consuming. To develop an efficient screening method, various genotyping platforms have been evaluated. However, as a result of the large number of RP genes identified to date, the fraction of patients in whom a mutation could be found by screening the known genes has often been low.

The purposes of this project were to evaluate a high-throughput genotyping assay, the GoldenGate assay with VeraCode microbeads, for mutation genotyping, and to find the frequent disease-causing mutations in Korean patients with RP. The genotyping platform with VeraCode microbeads is known to be flexible in assay content and multiplexing analytes, and can serve medium- to high-throughput applications \[[@r26]\]. With this technology, researchers have an optimal combination of assay content for each population. However, the platform used in this study also shows a limitation in the selection of mutations for the 96-well format, which may introduce strong selection bias in assay design. In addition, of 95 sequence variants that were selected to screen disease-causing mutations in a Korean population and to verify the assay platform, five mutations failed to detect genotypes because of the poor separation of clusters. A total of 12 mutations in six RP genes were identified and validated in this study. As independent verification of the ability of the GoldenGate assay, four DNA samples with known *RHO* mutations (p.T17M, p.K296N, and p.P347L) were analyzed. Genotype inconsistency between the GoldenGate assay and sequence analysis was observed in three mutations ([Figure 2](#f2){ref-type="fig"}), although the GoldenGate assay detected all previously known mutations in samples for validation. For rare variants, genotyping technologies must accurately perform two-cluster calling. Miscalling is usually characterized by heterozygous samples being assigned a homozygous mutant genotype for rare variants and vice versa for X-linked variants \[[@r27]\]. In the present study, incorrect two-cluster calling was observed in 3/11 (27%) rare autosomal variants. Customized genotyping assays are being used for mutation screening, frequency determination, and validation in investigations of disease-causing rare variants. For these applications, genotyping technologies, including the GoldenGate assay with VeraCode microbeads, should be improved in two-cluster calling for rare variants as well as in design flexibility of the assay probe.

In the RP-0089 family, a proband (III-2) inherited an *RHO* mutation (p.R135W) from the mother with ADRP and a mutant allele from the father with ARRP. Although the disease-causing gene of paternal pedigree is unknown, the mutant allele from the father may play a role as a modifier, either by directly influencing the function of the unknown gene or by interacting with the environment. Therefore, the phenotypic analysis and prognostic follow-up study of the patient (III-2) who received an ARRP mutation as well as an ADRP mutation would be meaningful.

Although Jin et al. have previously reported the p.T604I mutation of the *PDE6B* gene in Japanese patients and it was expected to be pathogenic \[[@r20]\], we could not confirm the association of p.T604I with RP in our samples due to absence of any patient with a homozygous mutation. Sequence analysis of the whole *PDE6B* gene in the heterozygote for the p.T604I mutation is necessary to determine whether the mutation is associated with compound heterozygous ARRP.

The characterization of genotype--phenotype correlations in patients with mutations was also one of the main purposes of the present study. The mode of inheritance is believed to play an important role in determining the prognosis of the disease. In general, ADRP has the slowest progression, and X-linked RP tends to induce the most severe form of the disease \[[@r23],[@r28]\]. Most mutations identified in our study are known to be related to ADRP or ARRP heritance. OCT is widely used to study retinal diseases and has been used to diagnose and monitor RP. Several studies using OCT have revealed that the retinal thickness and the status of inner and outer segments of the photoreceptor layer are correlated with visual acuity, and are significant factors for visual acuity in RP patients \[[@r29],[@r30]\]. In our study, comparing the phenotypes in patients with other mutations by foveal thickness and visual acuity after correcting for age, a patient with p.D984G in *RP1* had the most severe foveal atrophy with subsequent severe deterioration of visual acuity, despite this patient's young age of 29 years. In contrast, a patient with p.D190N in *RHO* had a normal range of foveal thickness and relatively good visual acuity, although this patient was the oldest at 59 years. Although the mutation of p.D984G in *RP1* was the first to be reported in Chinese patients, the clinical features were not described at that time \[[@r23]\]. Therefore, the severe phenotype associated with this mutation is first reported in our study. The mild phenotype of p.D190N in *RHO* is consistent with that in a previous study \[[@r31]\]. However, another mutation in the same *RHO* gene, p.R135W, caused more severe and more rapidly progressive RP than p.D190N, which is comparable to the observations in a previous study \[[@r32]\]. Interestingly, fundus findings in patients with p.T494M in *PRPF3* showed areas of atrophy along the arcades, which is similar to the results of a previous study in a Swiss family \[[@r33]\].

Although CME has been frequently described in RP patients and its prevalence has been reported to be 13%--49% using OCT \[[@r34],[@r35]\], the risk factors, including the specific genotype associated with CME in RP, have not been previously elucidated. In the present study, using OCT, we found CME in patients with p.T494M in *PRPF3* and p.H557Y in *PDE6B*. In our previous study, OCT revealed bilateral CME in all four children of a family with p.P347L in *RHO* \[[@r18]\]. These results indicate that CME in RP patients may be associated with a specific genotype. Further investigations of the risk factors for RP-associated CME in a larger cohort are required.

We carefully selected the assay content thought probable to occur in Korean RP patients. Nevertheless, only 10 RP-related mutations were identified in 26 (7.7%) of 336 patients. The most mutations identified in the study were previously detected in RP patients with East Asian ancestry, with the exception of p.D190N in *RHO* ([Table 2](#t2){ref-type="table"}). This suggests that the spectrum of mutations causing RP is more different than we expected in a population-specific manner. In previous studies, screening known genes in ADRP families led to the identification of a disease-causing mutation in 60% of cases among Americans of European ancestry and less frequently among other populations \[[@r36],[@r37]\]. Furthermore, less than 50% of RP patients had known inheritance patterns in the present study ([Table 1](#t1){ref-type="table"}). These factors likely explain why a small number of mutations were identified in the present study. Continuous effort to identify novel RP genes and mutations in a population would improve the efficiency and accuracy of the genetic diagnosis of RP. As a rapid and efficient way of finding disease-causing mutations, next-generation sequencing technologies could be useful in designing the best assay content for genetic diagnosis of RP in different populations. A rapid and reliable diagnostic tool for RP and its complete phenotypic characterization may enable patients and their families to receive appropriate genetic counseling and may contribute to the development of gene- or mutation-specific treatments.
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Variants previously reported in east Asians are underlined. Chr, chromosome; n, number of mutations. To access these data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v18/a253/app-1.pdf)." This will initiate the download of a compressed (pdf) archive that contains the file.

To access these data, click or select the words "[Appendix 2](http://www.molvis.org/molvis/v18/a253/app-2.pdf)." This will initiate the download of a compressed (pdf) archive that contains the file.
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